Microviable Therapeutics SL

Developing novel biological drugs based on the microbiome to address unmet challenges in human diseases.

Founded 2016 Spain

Spain 12 employees Seed Total: $1.50M Health Care, Life Sciences

Microviable Therapeutics SL is a biotech startup dedicated to developing novel biological drugs based on the microbiome to address unmet challenges in infectious diseases, oncology, and dermatology. The company's PharmaBiota® platform and proprietary technology have enabled the creation of two distinct product categories: complete microbiota ecosystem products and defined bacterial consortia. These groundbreaking technologies and products have been safeguarded through patents, trade secrets, and trademarks, resulting in a growing portfolio of intellectual property. The lead candidate MVT-201 is a donor-derived complete microbiota ecosystem that has completed preclinical testing and is scheduled to enter clinical trials in 2024 for the treatment of multi-drug resistant infectious diseases. Additionally, two other products are currently in development with preliminary in vitro data available. In pursuit of its mission, Microviable has established collaborative relationships with clinical and research organizations internationally, positioning the company at the forefront of microbiome science. Founded in 2016 as a spinoff of the Spanish National Research Council (CSIC), Microviable was established by five distinguished research scientists and a seasoned business development professional with extensive experience in pharmaceutical companies. The company, headquartered in Spain, currently boasts a team of 10 highly qualified employees and has achieved notable recognition, including the European Seal of Excellence, national and regional awards, and the certificate of Innovative SME. Microviable is actively seeking collaboration agreements with pharmaceutical and biotech companies to license the biological drugs it is developing, while also exploring potential partnerships to enhance its capabilities in strategic therapeutic areas of interest. In summary, Microviable Therapeutics represents a promising venture in the biotech industry, leveraging innovative technology and a comprehensive product pipeline to address critical unmet medical needs.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	€1.50M	1	Immunomet Intolerance and Dysbiosis	19 Apr 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

€1.50M

Immunomet Intolerance and Dysbiosis

19 Apr 2022

FAQ About Microviable Therapeutics SL

Developing novel biological drugs based on the microbiome to address unmet challenges in human diseases.

Microviable Therapeutics SL was founded in 2016.

Microviable Therapeutics SL is headquartered in Spain.

Microviable Therapeutics SL operates in Health Care and Life Sciences. Its work centres on biotech, microbiome, biological drugs and infectious diseases.

Microviable Therapeutics SL has approximately 12 employees.

Microviable Therapeutics SL has completed 1 funding round, raising a total of $1.50M. The latest funding stage is Seed.

Top alternatives and competitors to Microviable Therapeutics SL include Scioto Biosciences, Inc, ALX Oncology, Global Clinical Trials (GCT), Odimma Therapeutics, Scorpion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Microviable Therapeutics SL and Scioto Biosciences, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Microviable Therapeutics SL

General Information

Discover More

About Microviable Therapeutics SL

Funding Rounds & Investors (1)

Microviable Therapeutics SL Alternatives & Competitors

FAQ About Microviable Therapeutics SL